

Haematologica
HAEMATOL/2019/225557
Version 3
Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia
expressing CD19

Adriana Plesa, H el ene Labussier e-Wallet, Sandrine Hayette, Gilles Salles, Xavier Thomas, and Pierre Sujobert

Disclosures: Gilles Salles has received financial compensations for participating to advisory boards, consulting, or educationnal events from : Abbvie, Amgen, Celgene, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, Morphosys, Novartis, Roche, Servier, Takeda

Contributions: AP, HLW, SH, GS, XT and PS designed the study, analysed the data and wrote the paper